On 13 May 2024, Novo Nordisk announced positive results from the FRONTIER 2 trial, a 26-week phase 3a study evaluating the efficacy and safety of once-weekly and once-monthly subcutaneous administration of Mim8 for the treatment for haemophilia A. The study demonstrated that Mim8, a FVIIIa bispecific antibody, significantly reduced treated bleeding episodes across both treatment groups and was found to be safe and well-tolerated.
Novo Nordisk plans to seek regulatory approval for Mim8 by late 2024 and will present additional data in upcoming conferences and publications.
This news follows the 10 April 2024 announcement of Novo Nordisk’s partnership with Ginkgo Bioworks.